KR20200133003A - 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 - Google Patents

과다운동성 운동 장애의 치료를 위한 vmat2 억제제 Download PDF

Info

Publication number
KR20200133003A
KR20200133003A KR1020207032879A KR20207032879A KR20200133003A KR 20200133003 A KR20200133003 A KR 20200133003A KR 1020207032879 A KR1020207032879 A KR 1020207032879A KR 20207032879 A KR20207032879 A KR 20207032879A KR 20200133003 A KR20200133003 A KR 20200133003A
Authority
KR
South Korea
Prior art keywords
htbz
dimethoxy
isobutyl
pyrido
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207032879A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 에프. 오브라이언
Original Assignee
뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로크린 바이오사이언시즈 인코퍼레이티드 filed Critical 뉴로크린 바이오사이언시즈 인코퍼레이티드
Priority to KR1020227034399A priority Critical patent/KR20220140647A/ko
Publication of KR20200133003A publication Critical patent/KR20200133003A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020207032879A 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 Ceased KR20200133003A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227034399A KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167033765A Division KR20160147044A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034399A Division KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Publications (1)

Publication Number Publication Date
KR20200133003A true KR20200133003A (ko) 2020-11-25

Family

ID=53264772

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207032879A Ceased KR20200133003A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020257005033A Pending KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020227034399A Ceased KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020247001490A Ceased KR20240011255A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020167033765A Ceased KR20160147044A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020257005033A Pending KR20250029267A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020227034399A Ceased KR20220140647A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020247001490A Ceased KR20240011255A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제
KR1020167033765A Ceased KR20160147044A (ko) 2014-05-06 2015-05-06 과다운동성 운동 장애의 치료를 위한 vmat2 억제제

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3139925B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20200133003A (enExample)
CN (3) CN106456629A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3139925T3 (enExample)
ES (2) ES2976207T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20220025T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3139925T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3936130T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3139925T1 (enExample)
SM (2) SMT202200193T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000121A1 (en) 2015-10-30 2019-10-04 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
JP2020508337A (ja) 2017-02-27 2020-03-19 サンド・アクチエンゲゼルシヤフト バルベナジン塩の結晶形態
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
EP3606529A1 (en) * 2017-04-01 2020-02-12 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
US20200276184A1 (en) 2017-09-21 2020-09-03 Neurocrine Biosciences, Inc. High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EA202090932A1 (ru) 2017-10-10 2021-05-20 Нейрокрин Байосайенсиз, Инк Способы введения некоторых vmat2-ингибиторов
JP2021503009A (ja) * 2017-11-08 2021-02-04 フォアシー ファーマシューティカルズ シーオー．，リミテッド ジヒドロテトラベナジンのエステル
CN110621674B (zh) 2017-12-26 2022-03-29 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto
JP2021528481A (ja) 2018-08-15 2021-10-21 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２阻害剤を投与するための方法
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
JOP20210274A1 (ar) * 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) * 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
SI3061760T1 (en) 2008-09-18 2018-04-30 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
EP2576552A4 (en) * 2010-06-01 2013-11-13 Aupex Pharmaceutical Inc BENZOQUINOLONE INHIBITORS OF VMAT2
EP4345100A3 (en) * 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6718376B2 (ja) * 2014-02-07 2020-07-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用

Also Published As

Publication number Publication date
RS65359B1 (sr) 2024-04-30
CA2947736C (en) 2023-04-18
JP2017514850A (ja) 2017-06-08
AU2015256012A1 (en) 2016-11-24
RU2016147523A (ru) 2018-06-08
MX387625B (es) 2025-03-18
HUE057839T2 (hu) 2022-06-28
EP4389227A2 (en) 2024-06-26
EP3936130A1 (en) 2022-01-12
RS62782B1 (sr) 2022-01-31
KR20220140647A (ko) 2022-10-18
PL3139925T3 (pl) 2022-03-21
RU2016147523A3 (enExample) 2018-12-28
ES2904526T3 (es) 2022-04-05
CN106456629A (zh) 2017-02-22
PT3139925T (pt) 2022-01-26
EP3936130B1 (en) 2024-02-14
MX2016014429A (es) 2017-04-06
HRP20240459T1 (hr) 2024-06-21
JP2021191799A (ja) 2021-12-16
FI3936130T3 (fi) 2024-04-23
CA2947736A1 (en) 2015-11-12
JP2024153782A (ja) 2024-10-29
EP4389227A3 (en) 2024-09-04
HUE066361T2 (hu) 2024-07-28
JP2019218407A (ja) 2019-12-26
KR20250029267A (ko) 2025-03-04
SI3139925T1 (sl) 2022-04-29
AU2015256012B2 (en) 2020-07-23
IL248745A0 (en) 2017-01-31
PT3936130T (pt) 2024-04-17
US20170071932A1 (en) 2017-03-16
PL3936130T3 (pl) 2024-06-10
JP6635945B2 (ja) 2020-01-29
SI3936130T1 (sl) 2024-05-31
SMT202200193T1 (it) 2022-07-21
CY1125058T1 (el) 2023-06-09
US20210196702A1 (en) 2021-07-01
RU2753740C2 (ru) 2021-08-23
ES2976207T3 (es) 2024-07-26
US20200101063A1 (en) 2020-04-02
DK3936130T3 (da) 2024-03-25
EP3139925A1 (en) 2017-03-15
LT3936130T (lt) 2024-04-25
CN112741836A (zh) 2021-05-04
IL248745B (en) 2022-07-01
KR20240011255A (ko) 2024-01-25
KR20160147044A (ko) 2016-12-21
LT3139925T (lt) 2022-01-25
DK3139925T3 (da) 2021-12-20
SMT202400199T1 (it) 2024-07-09
EP3139925B1 (en) 2021-12-01
WO2015171802A1 (en) 2015-11-12
CN112741835A (zh) 2021-05-04
HRP20220025T1 (hr) 2022-04-01
NZ725826A (en) 2023-05-26

Similar Documents

Publication Publication Date Title
US20210196702A1 (en) Treatment of hyperkinetic movement disorders
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
US20080255079A1 (en) Therapeutic Use of Nefopam and Analogues Thereof
US20230355618A1 (en) Raf inhibitor for treating low grade glioma
HK40111840A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
EP3664787B1 (en) Use of selective serotonin 5-ht1a receptor agonists for treating side-effects of vmat inhibitors
JP2019524682A (ja) 抗うつ作用の速い発現のためのボルチオキセチン投与計画
HK40067005A (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK1235303A1 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
HK40067005B (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
EP2255807A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem
US20080070952A1 (en) Inhibition or Treatment of Dyskinesia
TW201345528A (zh) 用於組合療法之醫藥組合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20201113

Application number text: 1020167033765

Filing date: 20161201

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201211

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211029

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220504

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211029

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221004

Application number text: 1020167033765

Filing date: 20161201